Adicet Opens Enrollment For ADI-270 Phase 1 Clinical Trial In Metastatic/Advanced Clear Cell Renal Cell Carcinoma; First Gamma Delta CAR T Cell Therapy With The Potential To Address Solid Tumors Entering Clinical Trials; Preliminary Phase 1 Clinical...
Adicet Opens Enrollment For ADI-270 Phase 1 Clinical Trial In Metastatic/Advanced Clear Cell Renal Cell Carcinoma; First Gamma Delta CAR T Cell Therapy With The Potential To Address Solid Tumors Entering Clinical Trials; Preliminary Phase 1 Clinical...
愛文思控股啓動了ADI-270相1臨床試驗的招募工作，針對轉移性/晚期透明/愛文思控股性腎細胞癌；首個可能應對實體瘤的伽馬三角體CAR T細胞療法即將進入臨床試驗；初步相1臨床...
Adicet Opens Enrollment For ADI-270 Phase 1 Clinical Trial In Metastatic/Advanced Clear Cell Renal Cell Carcinoma; First Gamma Delta CAR T Cell Therapy With The Potential To Address Solid Tumors Entering Clinical Trials; Preliminary Phase 1 Clinical Data Expected In The First Half Of 2025
艾切託開放對轉移性/愛文思控股透明細胞腎細胞癌的ADI-270第一階段臨床試驗的招募；首個有潛力解決實體腫瘤的伽馬δ CAR t 電芯療法進入臨床試驗；初步第一階段臨床數據預計在2025年上半年發佈。
First gamma delta CAR T cell therapy with the potential to address solid tumors entering clinical trials
首個有潛力解決實體腫瘤的伽馬δ CAR t 電芯療法進入臨床試驗。
Preliminary Phase 1 clinical data expected in the first half of 2025
初步第一階段臨床數據預計在2025年上半年發佈。
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-270 in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC).
艾切託公司（納斯達克：ACET）是一家臨床階段的生物技術公司，專注於發現和開發用於自身免疫疾病和癌症的異體伽馬δ t 電芯療法，今天宣佈對轉移性/愛文思控股透明細胞腎細胞癌（ccRCC）患者進行ADI-270第一階段臨床試驗的招募已開啓。
熱門討論
特朗普2.0時代倒計時！全球股市的下一個風口？
🎙️️討論： 1. 加密貨幣政策能否利好crypto? 2. 關稅政策能否利好中概等海外資產？
Michael McCarthy CCO
01/03 11:57
賣盤分析師 - 川普的第一天